SEARCH

SEARCH BY CITATION

References

  • 1
    Harik NS, Smeltzer MS. Management of acute hematogenous osteomyelitis in children. Expert Rev Anti Infect Ther 2010; 2: 175181.
  • 2
    Krogstad P. Osteomyelitis and septic arthritis. In: Feigin RD, Cherry JD, eds, Pediatric infectious diseases, 6th edn, Vol. 1. Philadelphia, PA: Saunders, 2009; 725748.
  • 3
    Dich VQ, Nelson JD, Haltalin KC. Osteomyelitis in infants and children. A review of 163 cases. Am J Dis Child 1975; 129: 12731278.
  • 4
    Syrogiannopoulos GA, Nelson JD. Duration of antimicrobial therapy for acute suppurative osteoarticular infections. Lancet 1988; 1: 3740.
  • 5
    Toziano RR, Roncoroni JM, Lopardo H et al. Artritis infecciosa en el paciente pediatrico. Experiencia sobre 135 casos. Medicina Infantil 1993; 1: 6471.
  • 6
    Ross JJ, Saltzman CL, Carling P, Shapiro DS. Pneumococcal septic arthritis: review of 190 cases. Clin Infect Dis 2003; 36: 319327.
  • 7
    LeFrock J, Ristuccia A. Teicoplanin in the treatment of bone and joint infections: an open study. J Infect Chemother 1999; 5: 3239.
  • 8
    Cole WG, Dalziel RE, Leitz S. Treatment of acute osteomyelitis in childhood. J Bone Joint Surg 1982; 64B: 218223.
  • 9
    Zaki A, Schreiber EC, Weliky I, Knill JR, Hubsher JA. Clinical pharmacology of oral cephradine. J Clin Pharmacol 1974; 14: 118126.
  • 10
    Feigin RD, Pickering LK, Anderson D, Keeney RE, Schackleford PG. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics 1975; 55: 213223.
  • 11
    Nelson JD, Howard JB, Shelton S. Oral antimicrobial therapy for skeletal infections in children. I. Antimicrobial concentrations in suppurative synovial fluid. J Pediatr 1978; 92: 131134.
  • 12
    Peltola H, Pääkkönen M, Kallio P, Kallio MJT, The OM-SA Study Group. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis 2009; 48: 12011210.
  • 13
    Peltola H, Pääkkönen M, Kallio P, Kallio MJT, The OM-SA Study Group. Short-versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases. Pediatr Infect Dis J 2010; 29: 11231128.
  • 14
    Pääkkönen M, Kallio MJT, Peltola H, Kallio PE. Pediatric septic hip with or without arthrotomy: retrospective analysis of 62 consecutive nonneonatal culture-positive cases. J Pediatr Orthop B 2010; 19: 264269.
  • 15
    Peltola H, Vahvanen V. Acute purulent arthritis in children. Scand J Infect Dis 1983; 15: 7580.
  • 16
    Peltola H, Kallio MJT, Unkila-Kallio L. Reduced incidence of septic arthritis in children by Haemophilus influenzae type-b vaccination. Implications for treatment. J Bone Joint Surg Br 1998; 80-B: 471473.
  • 17
    Odio CM, Ramírez T, Arias G et al. Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J 2003; 22: 883888.
  • 18
    Peltola H, Räsänen JA. Quantitative C-reactive protein in relation to erythrocyte sedimentation rate, fever, and duration of antimicrobial therapy in bacteraemic diseases of childhood. J Infect 1982; 5: 257267.
  • 19
    Peltola H, Vahvanen V, Aalto K. Fever, C-reactive protein and erythrocyte sedimentation rate in monitoring recovery from septic arthritis. J Pediatr Orthop 1984; 4: 170174.
  • 20
    Unkila-Kallio L, Kallio MJT, Peltola H. The usefulness of C-reactive protein levels in the identification of concurrent septic arthritis in children who have acute hematogenous osteomyelitis. A comparison with the usefulness of the erythrocyte sedimentation rate and the white blood-cell count. J Bone Joint Surg 1994; 76-A: 848853.
  • 21
    Roine I, Faingezicht I, Arguedas A, Herrera JF, Rodríguez F. Serial serum C-reactive protein to monitor recovery from acute hematogenous osteomyelitis in children. Pediatr Infect Dis J 1995; 14: 4044.
  • 22
    Peltola H, Jaakkola M. C-reactive protein in early detection of bacteremic versus viral infections in immunocompetent and compromised children. J Pediatr 1988; 113: 641646.
  • 23
    Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003; 51: 12611268.
  • 24
    Uçkay I, Assal M, Legout L et al. Recurrent osteomyelitis caused by infection with different bacterial strains without obvious source of reinfection. J Clin Microbiol 2006; 44: 194196.
  • 25
    Howard JB, Highboten CL, Nelson JD. Residual effects of septic arthritis in infancy and childhood. JAMA 1976; 236: 932935.
  • 26
    Le Saux N, Howard A, Barrowman NJ, Gaboury I, Sampson M, Moher D. Shorter courses of parenteral antibiotic therapy do not appear to influence response rates for children with acute hematogenous osteomyelitis: a systematic review. Available at: http://www.biomedcentral.com/1471-2334/2/16 (last accessed 24 September 2011).
  • 27
    Faden D, Faden HS. The high rate of adverse events in children receiving prolonged outpatient parenteral antibiotic therapy for osteomyelitis. Pediatr Infect Dis J 2009; 28: 539541.
  • 28
    Martínez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22: 593598.
  • 29
    Chen CJ, Chiu CH, Lin TY et al. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007; 26: 985988.
  • 30
    Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 2009; 28: 149151.